SCHEMBL1461631

SCHEMBL1461631

COCC1CCCC[N]1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL170744 0.93
SCHEMBL170981 0.93
SCHEMBL173550 0.93
SCHEMBL5786025 0.80
SCHEMBL1219812 0.78
SCHEMBL6635003 0.78 CYP2D6 (0.31)
SCHEMBL8860690 0.77
SCHEMBL6050209 0.74 ALDH1A1 (0.32)
SCHEMBL693202 0.73
SCHEMBL11103722 0.73 NOS1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024045066-A1 ALKYLIDENE CARBAMATE AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2024-03-07 WO claimed
WO-2024046406-A1 ALKYLIDENE CARBAMATE AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2024-03-07 WO claimed
CN-114126713-B Substituted benzimidazolone compounds 百时美施贵宝公司 2023-12-08 CN claimed
US-20220289739-A1 SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2022-09-15 US claimed
CN-114126713-A Substituted benzimidazolone compounds 百时美施贵宝公司 2022-03-01 CN claimed
WO-2020227484-A1 SUBSTITUTED BENZIMIDAZOLONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2020-11-12 WO claimed
US-4925849-A DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-15 US claimed
EP-0299209-A2 Pyrazolopyridine compound and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-01-18 EP claimed
WO-2024149214-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS-12D VIA UBIQUITIN PROTEASOME PATHWAY NIKANG THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
WO-2024138486-A1 TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2024-07-04 WO disclosed
WO-2024051721-A1 TETRACYCLIC DERIVATIVES AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
WO-2024050742-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY NIKANG THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
WO-2024046406-A1 ALKYLIDENE CARBAMATE AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2024-03-07 WO disclosed
WO-2024045066-A1 ALKYLIDENE CARBAMATE AS KRAS INHIBITORS NIKANG THERAPEUTICS, INC. (US) 2024-03-07 WO disclosed
US-5102878-A Treating psychological, bone, cardiovascular, blood disorders FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-04-07 US disclosed
US-5087629-A Diuretics, hypotensive agents; cardiotonic agents FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-02-11 US disclosed
US-4994453-A Treating asthma, diabetes, obesity, immunosuppression FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-02-19 US disclosed
US-4925849-A DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) 1990-05-15 US disclosed
EP-0360701-A1 Antifungal compounds containing amides and phenyl groups RHONE-POULENC AGROCHIMIE (FR) 1990-03-28 EP disclosed
EP-0299209-A2 Pyrazolopyridine compound and processes for preparation thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1989-01-18 EP disclosed